Efficacy of SN132D in Patients With Suspected Endometriosis
Summary
This is a Phase IIa, open-label, non-randomised and non-placebo-controlled study. The study is designed to evaluate the diagnostic value and safety of a single intravenous dose of SN132D in up to 18 participants with suspected endometriosis. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.
Timeline
- Start
- 2022-11-17
- Primary completion
- 2023-06-20
- Completion
- 2023-09-12
Outcome
Met primary endpoint
release “A preliminary analysis of data from the phase IIa clinical study SPAGOPIX-02 shows that SN132D has a good safety profile in patients with endometriosis.” reads as unknown spagonanomedical.se ↗
release “Further evaluation of the MRI contrast enhancing properties, particularly in lesions indicative of deep endometriosis, is ongoing.” reads as unknown spagonanomedical.se ↗
release “SPAGOPIX-02 med kontrastmedlet pegfosimer manganese (tidigare benämnt SN132D) bekräftar att det primära effektmåttet kontrastverkan vid MRT i endometrioslesioner har uppnåtts.” reads as met primary endpoint spagonanomedical.se ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SN132D | Unknown | 0.02 mmol | — |